Info

Healtheuniverse is developing and intends to commercialize stem cell and regenerative medicine therapies utilizing non-embryonic adult stem cells for use in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Headquartered in Covina, CA, Healtheuniverse is a publicly traded California Corporation. The Company operates research and development in Singapore under the wholly owned subsidiary Healtheuniverse Pte.Ltd. We are currently collaborating and advancing the Company's stem cell technology in partnership with the following organizations: C.I.C.R.S.We have an exclusive agreement with The California Institute of Cosmetic and Reconstructive Surgery (C.I.C.R.S.) to conduct clinical trials in the United States for our fat based stem cell applications in the areas of cosmetic, plastic, and reconstructive surgery. Under the terms of this agreement, CICRS will manage a series of clinical trials intended to examine the safety and efficacy of our fat based stem cell therapies for the treatment of cosmetic, plastic, and reconstructive patients. Upon regulatory approval of the products, Healtheuniverse will be the exclusive distributor of products cleared for marketing. Healtheuniverse has a strategic alliance and approved grant status from the Economic Development Board of Singapore. The grant covers up to 30% of all preclinical R&D costs in Singapore with Healtheuniverse retaining 100% of all royalty and commercial rights. The EDB Biomedical Sciences Group (EDB BMSG) is responsible for the development of the Biomedical Sciences industry. The BMSG works closely with A*STAR's Biomedical Research Council (BMRC), Bio*One Capital and other agencies to develop human, intellectual, and industrial capital in Singapore, in support of the Biomedical Sciences industry.